Company Cell Therapeutics Inc Nasdaq
Equities
US1509348835
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2023 | DRI Healthcare Trust Receives US$54.8 Million in Debt Repayment | MT |
2023 | DRI Healthcare Trust Brief: Announcing US$54.8 Million Debt Repayment from CTI BioPharma Corp. | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Adam Craig
CEO | Chief Executive Officer | 58 | 17-03-19 |
David Kirske
DFI | Director of Finance/CFO | 69 | 17-07-31 |
John Volpone
HRO | Human Resources Officer | - | - |
Jim Fong
PRN | Corporate Officer/Principal | 62 | 07-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Adam Craig
CEO | Chief Executive Officer | 58 | 17-03-19 |
Laurent Fischer
CHM | Chairman | 60 | 17-07-20 |
David Parkinson
BRD | Director/Board Member | 73 | 17-06-04 |
Reed Tuckson
BRD | Director/Board Member | 73 | 11-08-31 |
Diane Parks
BRD | Director/Board Member | 71 | 21-08-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 3,047 | 0 | 0 | 95.47 % |
Stock B | 1 | 131,880,176 | 125,911,110 ( 95.47 %) | 0 |
Company contact information
CTI BioPharma Corp.
3101 Western Avenue Suite 800
98121, Seattle
+206 282 7100
http://www.ctibiopharma.comSector
1st Jan change | Capi. | |
---|---|---|
-1.82% | 41.36B | |
+44.25% | 41.3B | |
+2.56% | 39.61B | |
-12.11% | 25.62B | |
+3.09% | 24.09B | |
-24.16% | 18.38B | |
+22.12% | 11.85B | |
-3.74% | 11.82B | |
+7.75% | 11.07B |
- Stock Market
- Equities
- CTIC Stock
- Stock
- Company Cell Therapeutics Inc